News Releases
November 10, 2022
Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update
October 18, 2022
Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3
September 6, 2022
Synlogic Achieves Research Milestone in Collaboration with Roche for Development of Novel Synthetic Biotic to Treat Inflammatory Bowel Disease
August 23, 2022
Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU)
August 11, 2022
Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks
July 12, 2022
Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU)
June 21, 2022
Synlogic to Present at the 2022 HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation Conference
Displaying 37 - 48 of 222